A.D.A.M. Partners with SOPHiA for Liquid Biopsy Japan

A.D.A.M. Innovations, Japan’s leading private genetic testing company, has partnered with SOPHiA GENETICS. This global leader in AI data analytics targets precision medicine. They will work together to bring advanced liquid biopsy tests and companion diagnostics to Japan. The collaboration was announced at the ESMO Congress 2025 in Berlin. It’s an important step to improve access to precision oncology solutions for people in Japan.

A.D.A.M. Innovations has over 20 years of experience. They’ve completed more than 2.8 million genomic tests. Their lab in central Tokyo is one of Japan’s most advanced high-throughput facilities. The company is focused on bringing global innovation to Japanese healthcare. They are using the AI-powered SOPHiA DDM™ Platform. This will boost the speed, accuracy, and personalization of cancer tests nationwide.

The partnership will first launch the MSK-ACCESS® with SOPHiA DDM™ liquid biopsy app in Japan. This advanced test detects important genomic changes from just one blood sample. It uses AI to analyze circulating tumor DNA (ctDNA) with great accuracy. Using a matched tumor-normal approach, the test cuts down on false positives. This makes the results more reliable. Testing at A.D.A.M. Innovations’ Tokyo lab will quicken results. This will lower patient costs and give oncologists and researchers faster insights across the country.

こちらもお読みください： Shonan iPark and LabCentral Forge Strategic Partnership to Propel Asian Biotech Startups into U.S. Ecosystem

A.D.A.M. Innovations and SOPHiA GENETICS will team up to develop a liquid biopsy companion diagnostic (CDx) for Japan. The new CDx seeks to enhance access to precision oncology tools. It helps create treatment plans for each patient. Also, it helps pharmaceutical partners add high-quality tumor profiling to clinical trials and drug development. A.D.A.M. Innovations will use its strong regulatory and clinical knowledge. This will help with local validation and approval processes. They aim to meet Japan’s strict medical standards.

This partnership shows that both companies aim to enhance precision medicine through data. They aim to do this using advanced genomics and AI technology. A.D.A.M. Innovations is teaming up with SOPHiA GENETICS. Their strong clinical network and local know-how will boost cancer care in Japan. This partnership will make genomic testing more personal and less invasive for everyone.